Changes in humoral immune response after SARS‐CoV‐2 infection in liver transplant recipients compared to immunocompetent patients

The protective capacity and duration of humoral immunity after SARS‐CoV‐2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti‐nucleocapsid IgG antibodies in liver transplant recipients 6 months after...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of transplantation 2021-08, Vol.21 (8), p.2876-2884
Hauptverfasser: Caballero‐Marcos, Aránzazu, Salcedo, Magdalena, Alonso‐Fernández, Roberto, Rodríguez‐Perálvarez, Manuel, Olmedo, María, Graus Morales, Javier, Cuervas‐Mons, Valentín, Cachero, Alba, Loinaz‐Segurola, Carmelo, Iñarrairaegui, Mercedes, Castells, Lluís, Pascual, Sonia, Vinaixa‐Aunés, Carmen, González‐Grande, Rocío, Otero, Alejandra, Tomé, Santiago, Tejedor‐Tejada, Javier, Álamo‐Martínez, José María, González‐Diéguez, Luisa, Nogueras‐Lopez, Flor, Blanco‐Fernández, Gerardo, Muñoz‐Bartolo, Gema, Bustamante, Francisco Javier, Fábrega, Emilio, Romero‐Cristóbal, Mario, Martin‐Mateos, Rosa, Del Rio‐Izquierdo, Julia, Arias‐Milla, Ana, Calatayud, Laura, Marcacuzco‐Quinto, Alberto A., Fernández‐Alonso, Víctor, Gómez‐Gavara, Concepción, Colmenero, Jordi, Muñoz, Patricia, Pons, José A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The protective capacity and duration of humoral immunity after SARS‐CoV‐2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti‐nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID‐19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well‐known prognostic impact in COVID‐19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID‐19. Liver transplant recipients showed a lower incidence of anti‐nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p 
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.16599